HSBC Holdings reports $29.9 billion in pre-tax profit for 2025 and suspends share buybacks
HSBC Holdings (00005.HK) announced its 2025 results, reporting revenue of $68.3 billion, an increase of $2.4 billion, or 4%, compared to 2024; net interest income was $34.8 billion, an increase of $2.1 billion compared to 2024. Reported pre-tax profit decreased by $2.4 billion to $29.9 billion, primarily due to a net adverse impact of $4.9 billion from items requiring attention compared to the previous year. The Common Equity Tier 1 ratio remained at 14.9%. The Board has approved a fourth dividend of $0.45 per share, bringing the total dividend for 2025 to $0.75 per share. For 2026, based on current expectations for policy rates, HSBC expects net interest income from its banking operations to reach at least $45 billion. The bank intends to maintain its medium-term target range for the Common Equity Tier 1 (CET1) ratio at 14% to 14.5%. Furthermore, the bank expects to restore the CET1 ratio to the target range through organic capital generation and by refraining from initiating any further share buybacks until the CET1 ratio returns to or exceeds the target range.
Source:富途快讯 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
3
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
4
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
5
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
6
Ethereum Recent Rebound: Price Breaks Above $1,970, but Multiple Risks Remain
-
7
QUARTZ Coin Analysis: An Overview of the Sandclock (QUARTZ) and Unique Network’s Quartz (QTZ) Projects
-
8
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
9
Iran-linked exchange Shelbit allegedly sent $676 million to Binance in sanctions-evasion operation, Reuters reports
-
10
NVIDIA and AMD: The Two Giants of AI Computing Power in 2026—An Analysis of Market Dynamics, Financial Performance, and Opportunities for Transition into Cryptocurrency Mining
Markets Today
Recommended Reading









